Dosage & Administration Drug label People also ask

Tasigna

(nilotinib)

Tasigna 50 MG Oral CapsuleTasigna 150 MG Oral Capsule

View 1 more

Dosage & administration

* Recommended Adult Dose: Newly diagnosed Ph+ CML-CP: 300 mg orally twice daily. Resistant or intolerant Ph+ CML-CP and CML-AP: 400 mg orally twice daily.
* Recommended Pediatric Dose: Newly Diagnosed Ph+ CML-CP or Ph+ CML-CP and CML-AP resistant or intolerant to prior TKI therapy: 230 mg/m2 orally twice daily, rounded to the nearest 50 mg dose (to a maximum single dose of 400 mg).
* See Dosage and Administration for full dosing instructions and dose-reduction instructions for toxicity.
* Reduce starting dose in patients with baseline hepatic impairment.
* Eligible newly diagnosed adult patients with Ph+ CML-CP who have received Tasigna for a minimum of 3 years and have achieved a sustained molecular response (MR4.5) and patients with Ph+ CML-CP resistant or intolerant to imatinib who have received Tasigna for at least 3 years and have achieved a sustained molecular response (MR4.5) may be considered for treatment discontinuation.

drug label

Tasigna prescribing information

Report Adverse Event

PubMed™ | Tasigna

Tasigna PubMed™ News

Tasigna FAQs

How is the dosage of Tasigna?Tasigna is available in 3 dosages, including 150 mg Cap, 200 mg Cap and 50 mg Cap

What does Tasigna treat?Tasigna treats Accelerated Phase Myeloid Leukemia and Chronic-Phase Myeloid Leukemia

What is Tasigna made of?Tasigna contains nilotinib which is a Kinase Inhibitor

How Is Tasigna Administered?Tasigna is administered as a Oral Pill

What Are The Tasigna Mechanism Of Action?Tasigna mechanism of action is Protein Kinase Inhibitors

FAQ Data Source